4. Takahashi T, Lord B, Schulze PC, et al. Ascorbic acid enhances
differentiation of embryonic stem cells into cardiac myocytes. Circulation. 2003;
107(14): 1912-6.
5. Sánchez-Lázaro IJ, Almenar L, Reganon E, et al. Inflammatory markers
in stable heart failure and their relationship with functional class. Int J Cardiol.
2008; 129(3): 388-393.
6. Alonso-Martínez JL, Llorente-Diez B, Echegaray-Agara M, Olaz-
Preciado F, Urbieta-Echezarreta M, Gonzalez-Arencibia C. C-reactive protein as
a predictor of improvement and readmission in heart failure. Eur J Heart Failure.
2002; 4(3): 331-336.
7. Satoh M, Minami Y, Takahashi Y, Nakamura M. Immune modulation:
Role of the inflammatory cytokine cascade in the failing human heart. Curr Heart
Fail Rep. 2008; 5(2): 69-74.
8. Le Blanc K, Ringdén O. Immunomodulation by mesenchymal stem cells
and clinical experience. J Intern Med. 2007; 262(5): 509-525.
9. Keyser KA, Beagles KE, Kiem HP. Comparison of Mesenchymal stem
cells from different tissues to suppress t-cell activation. Cell Transplant. 2007;
16(5): 555-562.
10. Ortiz LA, DuTreil M, Fattman C, et al. Interleukin 1 receptor antagonist
mediates the antiin flammatory and antifibrotic effect of mesenchymal stem cells
during lung injury. Proc Natl Acad Sci U S A. 2007; 104(26): 11002-11007.
11. Madrigal M, Rao KS, Riordan NH. A review of therapeutic effects of
mesenchymal stem cell secretions and induction of secretory modification by
different culture methods. J Transl Med. 2014; 12(1): 260. doi: 10.1186/s12967-
014-0260-8.
12. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-γ does not break,
but promotes the immunosuppressive capacity of adult human mesenchymal stem
cells. Clin Exp Immunol. 2007; 149(2): 353-363.
13. Nishiyama N, Miyoshi S, Hida N, et al. The signifcant Cardiomyogenic
potential of human Umbilical cord blood-derived Mesenchymal stem cells in
vitro. Stem Cells. 2007; 25(8): 2017-2024.
